1v1 Institutional Counterparty Comparison
InBioGen vs JP Markets: Regulation, 6D Ratings & Safety Audit
Deterministic head-to-head benchmarking of InBioGen (InBioGen Co Ltd) and JP Markets (JP Markets) across primary regulatory filings, statutory Tier-1 authorisations, 6-Dimension compliance scores, execution software, and warning exposure.
Coverage: Selected financial institution records: Singapore, Asia-Pacific, the Middle East and emerging markets
InBioGen and JP Markets are statistically tied in composite 6D scoring (5.0 vs 5.0)
On supervisory breadth, InBioGen holds 0 active regulated licence(s) (0 Tier-1) out of 0 total filings and 0 warning count(s), whereas JP Markets holds 0 active regulated licence(s) (0 Tier-1) out of 0 total filings and 0 warning count(s). Allocators should inspect the individual licence numbers and contracting legal entities below before onboarding.
6-Dimension Quantitative Scorecard Comparison
Head-to-head breakdown across all 6 proprietary evaluation dimensions (0.0–10.0 scale).
| Evaluation Dimension | Methodology Weight | InBioGen | JP Markets | Score Delta | Dimension Leader |
|---|---|---|---|---|---|
| Overall Composite 6D Score | 100% Composite | 5.0 | 5.0 | 0.0 | Statistical Tie |
| Regulatory & Licensing Integrity (riskScore) | 30% Weight | 5.0 | 5.0 | 0.0 | Statistical Tie |
| Execution & Software Infrastructure (industryScore) | 20% Weight | 3.0 | 3.0 | 0.0 | Statistical Tie |
| User Reputation & Complaint Telemetry (userScore) | 20% Weight | 0.0 | 0.0 | 0.0 | Statistical Tie |
| Institutional Brand Longevity (brandScore) | 15% Weight | 5.0 | 5.0 | 0.0 | Statistical Tie |
| Global Market Influence & Footprint (influenceScore) | 15% Weight | 5.0 | 5.0 | 0.0 | Statistical Tie |
Visual Architecture Benchmark: InBioGen vs JP Markets
Vector comparison exhibit generated from live supervisory snapshot metrics.
Regulatory Standing, Entity & Platform Comparison
Structural comparison of supervisory authorisations, domicile, execution terminals, and risk telemetry.
| Audit Attribute | InBioGen | JP Markets |
|---|---|---|
| Primary Legal Name | InBioGen Co Ltd | JP Markets |
| Source Risk Classification | Risk level not supplied | Risk level not supplied |
| Active Regulated / Total Filings | 0 regulated / 0 total (0 Tier-1) | 0 regulated / 0 total (0 Tier-1) |
| Recorded Certificate Numbers | None on file | None on file |
| Registered Domicile / Address | 14F, 61, Digital-ro 26-gil, Guro-gu, Seoul, Republic of Korea | No.4 Century Falls Road, Century City, Cape Town, 7441 |
| Offered Asset Classes & Services | Multi-asset financial services | A wide range of traded assets including FX, stocks, indices and commodities |
| Execution Software & Terminals | Proprietary / Web Platform | Proprietary / Web Platform |
| Supported Client Languages | English | English |
| Warning / Exposure Count | 0 recorded warning(s) | 0 recorded warning(s) |
| Specialized Sub-Page Audits |
Related 1v1 Institutional Comparisons
Compare InBioGen and JP Markets against other regulated peers in our selected financial institution records: singapore, asia-pacific, the middle east and emerging markets slice.
Frequently Asked Questions: InBioGen vs JP Markets
Deterministic counterparty comparison answers derived from supervisory records.
Which institution has stronger regulatory oversight: InBioGen or JP Markets?
Both InBioGen and JP Markets hold 0 regulated licence record(s) in our dataset. Specifically, InBioGen maintains 0 total recorded filing(s) (none on file) with 0 warning flag(s), whereas JP Markets maintains 0 recorded filing(s) (none on file) with 0 warning flag(s). Always confirm the specific subsidiary onboarding your account on the official regulator register.
How do the 6D quantitative compliance scores compare between InBioGen and JP Markets?
In World Firm Ledger's 6-Dimension scoring matrix (0.0–10.0 scale), InBioGen records an Overall Score of 5.0 (Risk & Licensing: 5.0, Brand: 5.0, Market Influence: 5.0, User Reputation: 0.0, Execution & Software: 3.0), compared with JP Markets at 5.0 Overall (Risk & Licensing: 5.0, Brand: 5.0, Market Influence: 5.0, User Reputation: 0.0, Execution & Software: 3.0).
How do InBioGen and JP Markets differ in trading platforms and asset classes?
InBioGen lists general financial services with execution software [proprietary/web execution], while JP Markets lists A wide range of traded assets including FX, stocks, indices and commodities with execution software [proprietary/web execution]. Counterparties should verify FIX/API connectivity, server routing topology, and negative balance protection per entity.
Which counterparty carries lower regulatory warning and complaint exposure: InBioGen or JP Markets?
InBioGen carries a "Risk level not supplied" classification with 0 warning/exposure count(s) and 0 user comment(s), while JP Markets carries a "Risk level not supplied" classification with 0 warning/exposure count(s) and 0 user comment(s).
Structured against supervisory register snapshots and public regulatory filings. Verify your contracting legal entity and current authorisation status directly on the issuing regulator’s official register before transacting.
